Genocea Biosciences Inc. (GNCA) Given Average Rating of “Buy” by Analysts
Genocea Biosciences Inc. (NASDAQ:GNCA) has been given an average recommendation of “Buy” by the five ratings firms that are currently covering the stock. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $14.25.
A number of research firms have recently commented on GNCA. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Genocea Biosciences in a report on Thursday, September 29th. Piper Jaffray Cos. cut their price objective on Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, September 29th. FBR & Co restated a “buy” rating on shares of Genocea Biosciences in a report on Monday, August 8th. Finally, Zacks Investment Research downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 6th.
Shares of Genocea Biosciences (NASDAQ:GNCA) remained flat at $4.11 during trading on Tuesday. The stock had a trading volume of 78,492 shares. The company has a 50 day moving average price of $5.06 and a 200-day moving average price of $4.70. Genocea Biosciences has a 1-year low of $2.56 and a 1-year high of $8.07. The stock’s market cap is $116.45 million.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. Genocea Biosciences had a negative return on equity of 47.87% and a negative net margin of 5,121.17%. Analysts predict that Genocea Biosciences will post ($1.63) earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the stock. Schonfeld Strategic Advisors LLC bought a new stake in shares of Genocea Biosciences during the first quarter valued at approximately $565,000. Franklin Resources Inc. increased its stake in shares of Genocea Biosciences by 37.0% in the first quarter. Franklin Resources Inc. now owns 2,886,600 shares of the company’s stock valued at $22,342,000 after buying an additional 779,400 shares during the last quarter. Alpine Partners VI LLC bought a new stake in shares of Genocea Biosciences during the second quarter valued at approximately $120,000. Geode Capital Management LLC increased its stake in shares of Genocea Biosciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 136,990 shares of the company’s stock valued at $1,060,000 after buying an additional 1,743 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in shares of Genocea Biosciences during the second quarter valued at approximately $334,000. Institutional investors and hedge funds own 56.50% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.